| Hans-Günter Meyer-Thompson | Hepatitiden
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
Boyle A, Marra F, Peters E, Datta S, Ritchie T, Priest M, Heydtmann M, Barclay ST.
J Viral Hepat. 2020 Apr;27(4):371-375. doi: 10.1111/jvh.13239. Epub 2019 Dec 13. PMID: 31756019; PMCID: PMC7155106.